US-based clinical trials laboratory services organisation Q2 Solutions’ EA Genomics has entered into an agreement with Illumina to create a framework to develop next-generation sequencing-based (NGS) CDx assays.

The expansion of Q2 Solutions’ CDx development portfolio will boost its wide range of end-to-end services that extend from biomarker discovery and development to the application of precision medicine through its clinical trials laboratory network.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

According to the agreement, Q2 Solutions will develop NGS assays using Illumina’s MiSeqDx instrument.

"The industry is quickly moving toward a world of precision medicine, and we believe companion diagnostics are key to unlocking a new future for patients who are battling diseases."

Approved by the US Food and Drug Administration (FDA), the MiSeqDx is an NGS instrument used for in vitro diagnostic purposes in clinical laboratories.

This partnership will combine Q2 Solutions’ global experience and local knowledge, as well as its genomic, scientific and medical expertise, with Illumina’s ability to apply innovative technologies to the analysis of genetic variation and function.

See Also:

Q2 Solutions CEO Costa Panagos said: “At Q2 Solutions, we partner with our customers to bring innovative solutions to meet the needs of patients across the world.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The industry is quickly moving toward a world of precision medicine, and we believe companion diagnostics are key to unlocking a new future for patients who are battling diseases, such as cancer, where more targeted and accurate therapies are critical.

“Q2 Solutions helped develop 62% of all FDA-approved precision medicine drugs of 2015, and we look forward to the opportunity to continue working with our customers on an approach that can help improve healthcare globally.”